Elixir Medical is also working on LithiX Hertz Contact Intravascular Lithotripsy (IVL) System for calcium fragmentation in moderate to severe calcified coronary artery lesions during PCI procedure.

WASHINGTON, D.C. — Oct. X, 2024 — Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced positive six-month data from the PINNACLE I study ...

MILPITAS, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Elixir Medical, a developer of disruptive technologies to treat cardiovascular disease, today announced EU MDR CE Mark approval and commercial ...

Elixir Medical has joined the growing intravascular lithotripsy (IVL) market following the CE marking of its LithiX Hertz Contact system. The LithiX device employs focal stress contact points to ...

BIOADAPTOR RCT trial is the third trial of Elixir Medical’s robust DynamX ® bioadaptor clinical evidence program consisting of nine company-sponsored and investigator-initiated studies ...

In her 20 years since medical school, the oldest patient Rodgers ... But, if there is an elixir getting 54-year-olds pregnant, I'm sure the whole world would be on it." ...

MILPITAS, Calif., March 18, 2025--(BUSINESS WIRE)--Elixir Medical is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list ...